Retrophin secures more cash, buys 'potential $100m' drug
This article was originally published in Scrip
Executive Summary
Retrophin has had a busy end to the month of May; the New York-based company has acquired the US marketing rights to off-patent cystinuria drug Thiola and has secured an $80m loan facility through Athyrium Capital Management.